ACLARION, INC. Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
ACLARION, INC. (ACON) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $385.55 thousand as of 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2023-11-14
- 2023-09-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $385.55K.
- 2023-06-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $443.25K.
- 2023-03-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $501.19K.
- 2022-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $559.41K.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount |
|---|---|
| 2023-09-30 | $385.55K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $443.25K 10-Q · filed 2023-08-25 |
| 2023-03-31 | $501.19K 10-Q · filed 2023-07-03 |
| 2022-12-31 | $559.41K 10-K/A · filed 2023-06-12 |
| 2022-09-30 | $615.97K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |